Any research that mentions our "Youth Gene Clusters" sounds
very promising, especially if we believe we can stimulate our
youth genes to turn back the hands of time and live longer,
better and more beautifully. Research from Nu Skin Enterprises
, the global anti-aging products company, is about resetting the
With last year's revenue of $2.17 billion, up 24%, and new
product releases on the horizon, Nu Skin Enterprises Inc.
was top in the consumer goods sector last week. The company's
earnings per share have risen from $1.49 per share in 1998, to
current forecast earnings per share of approximately $3.77 to
$3.92 for fiscal 2013. A dividend contender, the company started
paying a dividend about 12 years ago and has paid a dividend
every year. Most recently, Nu Skin Enterprises Inc. paid a
quarterly dividend of $0.30 per share on March 13, 2013.
It's no wonder the anti-aging personal care products giant NUS is
on the keeps-buying list of a number of billionaire investor
Gurus. As of the quarter ending Dec. 31, 2012, Guru
, president and co-chief investment officer of Royce &
Associates, owns 7,414,768 shares of NUS, valued as $275 million.
This accounts for 0.89% of his equity portfolio.
added his NUS positions in the Sept. 30, 2012 quarter by 0.01%,
again in the Dec. 31, 2012 quarter by 8.07%.
Chuck Royce holding history:
Propelled by genetic and anti-aging research, Nu Skin Enterprises
Inc. is a global direct-selling company with operations in 52
markets worldwide. The company develops and distributes
anti-aging personal care products and nutritional supplements
sold under the Nu Skin and Pharmanex brands. Its new weight
management system will be released in the latter half of 2013.
In February the company announced record results with revenue of
$588.2 million in fourth quarter 2012, up 19% over the prior-year
period. Earnings per share for the quarter were $0.97, a 27%
The company also reported 2012 revenue of $2.17 billion, up 24%
year over year. Annual revenue was negatively impacted 1 percent
by foreign currency fluctuations. Earnings per share for the year
were $3.52, a 48% increase over 2011 (or 31% when excluding
charges related to a Japan customs case in the prior year).
Nu Skin Enterprises' Joseph Chang, Ph.D., the company's chief
scientific officer and executive vice president of product
development, explains the company approach: "Nu Skin's scientific
approach to anti-aging looks at the level of genetic expression
of aging and is supported by our partnerships with some of the
best minds in anti-aging science, such as our colleagues at
LifeGen Technologies. Identifying functional Youth Gene Clusters
and understanding how ingredients can target and reset those
genes to a more youthful profile helps us develop next-generation
skin care and nutritional products."
Nu Skin President and CEO Truman Hunt said, "We are pleased with
our solid fourth quarter results and believe 2013 will be another
record year as we launch a new wave of compelling anti-aging
products and project strong performances around the world."
The company reports its fourth quarter revenue by region as
"North Asia. Fourth-quarter revenue in North Asia was $250.2
million, compared to $204.3 million for the same period in 2011.
The region's results were negatively impacted approximately 1% by
foreign currency fluctuations. Japan local-currency revenue
improved 26% while South Korea experienced local-currency revenue
growth of 19%.
Greater China. In Greater China, fourth-quarter revenue increased
28% to $141.7 million, compared to $110.6 million in the
prior-year period. Foreign currency fluctuations had a positive
impact of 3% in the region.
South Asia/Pacific. Revenue in South Asia/Pacific was $63.5
million, a 3%t decline compared to the prior year. Sales in the
quarter were positively impacted 4% by foreign currency
Americas. Revenue in the Americas improved 4% to $80.1 million,
compared to $76.9 million in the prior-year period. Sales in the
U.S. increased 18% when excluding $12.5 million of convention
sales to non-U.S. distributors in the fourth quarter of 2011.
Europe. Revenue in Europe was $52.8 million, a 38% improvement
over the prior-year period. Results in the region were negatively
impacted 6% by foreign currency fluctuations."
Nu Skin Enterprises Inc. has a market cap of $2.46 billion; its
shares were traded at around $42.81 with a P/E ratio of 11.73 and
P/S ratio of 1.2. For a 12-month growth rate, Nu Skin Enterprises
shows revenue growth of 27.7% annual rate per share.
NUS revenue per share annual growth:
NUS data by GuruFocus.comAbout GuruFocus: GuruFocus.com tracks
the stocks picks and portfolio holdings of the world's best
investors. This value investing site offers stock screeners and
valuation tools. And publishes daily articles tracking the latest
moves of the world's best investors. GuruFocus also provides
promising stock ideas in 3 monthly newsletters sent to